Official Title: “A Pilot Study of Efficacy and Tolerability of Levetiracetam Monotherapy in Subjects With Childhood Absence Epilepsy”

Childhood absence epilepsy (CAE) is a form of generalized epilepsy syndrome. Clinically these seizures are manifest with a sudden, brief (3-15 second) loss of awareness followed by a quick recovery to baseline. Keppra (levetiracetam) is approved by the U.S. Food and Drug Administration (FDA) to treat partial seizures in adults. It is currently being studied in children with partial seizures. Absence seizures can be difficult to detect clinically, therefore the response to therapy will be determined both by clinical observation and by 24 hour EEG recordings. The researchers hope that with this information they will learn how well it works for the treatment of childhood absence epilepsy and at what dose. This is an open-label, dose-ranging pilot study of levetiracetam in subjects with newly diagnosed childhood absence epilepsy. Approximately 20 patients will be needed to study effectiveness and dose requirements. Subjects must not be on any antiepileptic medication at the time of entry into the study. Male and female subjects from the ages of 4 to 10 years of age may participate.

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Dose Comparison, Single Group Assignment, Safety/Efficacy Study

This is a 12 week ( 12 week treatment phase), dose ranging pilot study on the effectiveness of levetiracetam for the treatment of childhood absence epilepsy. It consists of 1 phase.

The treatment phase where the optimal medication dose will be defined. Absence seizures are often brief and subtle with no postictal manifestations. As a result, clinical observation alone is inadequate to assess the seizure Therefore, both subjective clinical response (parental/caregiver assessment) and EEG recordings are an important part of evaluation of treatment response. A 6 hour outpatient video-EEG study (including 3 minutes of hyperventilation), followed by an 18 hour ambulatory EEG recording - for total 24 hour EEG recording will be done before treatment and every 2 weeks after each dose plateau is reached )

Intervention(s) in this Clinical Trial

• Drug: Levetiracetam

Primary Measures

• The primary efficacy variable will be change in seizure frequency.

Secondary Measures

• Determine the design of a larger placebo controlled monotherapy study of the use of levetiracetam for CAE.

Inclusion Criteria:

• CAE by EEG criteria
• Naive to antiepileptics
• Onset 3 to 10 years old
• A history of daily seizures
• Age between 4 and 10
• Weight at least 5th percentile for age
• Be able to take oral medications
• Be willing to return for diagnostic testing and visits and adhere to medication regime

Exclusion Criteria:

• An EEG with any of the following abnormalities
• Focal epilepsy
• Slow spike and wave discharges
• Photoconvulsive response
• Slow background rhythms for age
• Currently being treated with an antiepileptic drug (AED)
• History of MR
• A history of myoclonic, atonic,tonic or astatic seizures
• A clinically unstable disease

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 4 Years

Maximum Age for this Clinical Trial: 10 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Sponsor: The Cleveland Clinic

Overall Clinical Trial Officials and Contacts

Deepak K Lachhwani, MD Principal Investigator The Cleveland Clinic, Division of Pediatric Neurology  

Information obtained from ClinicalTrials.gov on August 29, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00361010

Study ID Number: KeppraCAE

ClinicalTrials.gov Identifier: NCT00361010

Health Authority: United States: Institutional Review Board